TMO Quote, Financials, Valuation and Earnings

FONAR Corp. has a net margin of 16.21% compared to Thermo Fisher Scientific, Inc.'s net margin of 9.94%. Thermo Fisher Scientific, Inc.'s return on equity of 13.23% beat FONAR Corp.'s return on equity of 6.02%.

Thermo Fisher Scientific, Inc. has a consensus price target of $666.46, signalling upside risk potential of 30.44%. On the other hand FONAR Corp. has an analysts' consensus of -- which suggests that it could fall by --. Given that Thermo Fisher Scientific, Inc. has higher upside potential than FONAR Corp., analysts believe Thermo Fisher Scientific, Inc. is more attractive than FONAR Corp..

Thermo Fisher Scientific, Inc. has a beta of 0.928, which suggesting that the stock is 7.166% less volatile than S&P 500. In comparison FONAR Corp. has a beta of 1.002, suggesting its more volatile than the S&P 500 by 0.18499999999999%.

Thermo Fisher Scientific, Inc. has a quarterly dividend of $0.43 per share corresponding to a yield of 0.34%. FONAR Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Thermo Fisher Scientific, Inc. pays 9.7% of its earnings as a dividend. FONAR Corp. pays out -- of its earnings as a dividend. Thermo Fisher Scientific, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Thermo Fisher Scientific, Inc. quarterly revenues are $12.2B, which are larger than FONAR Corp. quarterly revenues of $25.5M. Thermo Fisher Scientific, Inc.'s net income of $2B is higher than FONAR Corp.'s net income of $2.5M. Notably, Thermo Fisher Scientific, Inc.'s price-to-earnings ratio is 28.80x while FONAR Corp.'s PE ratio is 16.52x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Thermo Fisher Scientific, Inc. is 4.33x versus 1.12x for FONAR Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly & Co. has a net margin of 16.21% compared to Thermo Fisher Scientific, Inc.'s net margin of 34.4%. Thermo Fisher Scientific, Inc.'s return on equity of 13.23% beat Eli Lilly & Co.'s return on equity of 104.39%.

Thermo Fisher Scientific, Inc. has a consensus price target of $666.46, signalling upside risk potential of 30.44%. On the other hand Eli Lilly & Co. has an analysts' consensus of $1,211.21 which suggests that it could grow by 19.98%. Given that Thermo Fisher Scientific, Inc. has higher upside potential than Eli Lilly & Co., analysts believe Thermo Fisher Scientific, Inc. is more attractive than Eli Lilly & Co..

Thermo Fisher Scientific, Inc. has a beta of 0.928, which suggesting that the stock is 7.166% less volatile than S&P 500. In comparison Eli Lilly & Co. has a beta of 0.388, suggesting its less volatile than the S&P 500 by 61.171%.

Thermo Fisher Scientific, Inc. has a quarterly dividend of $0.43 per share corresponding to a yield of 0.34%. Eli Lilly & Co. offers a yield of 0.62% to investors and pays a quarterly dividend of $1.73 per share. Thermo Fisher Scientific, Inc. pays 9.7% of its earnings as a dividend. Eli Lilly & Co. pays out 26.14% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Thermo Fisher Scientific, Inc. quarterly revenues are $12.2B, which are smaller than Eli Lilly & Co. quarterly revenues of $19.3B. Thermo Fisher Scientific, Inc.'s net income of $2B is lower than Eli Lilly & Co.'s net income of $6.6B. Notably, Thermo Fisher Scientific, Inc.'s price-to-earnings ratio is 28.80x while Eli Lilly & Co.'s PE ratio is 44.69x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Thermo Fisher Scientific, Inc. is 4.33x versus 14.11x for Eli Lilly & Co.. Usually stocks with elevated PS ratios are considered overvalued.

Sotera Health Co. has a net margin of 16.21% compared to Thermo Fisher Scientific, Inc.'s net margin of 15.55%. Thermo Fisher Scientific, Inc.'s return on equity of 13.23% beat Sotera Health Co.'s return on equity of 11.79%.

Thermo Fisher Scientific, Inc. has a consensus price target of $666.46, signalling upside risk potential of 30.44%. On the other hand Sotera Health Co. has an analysts' consensus of $20.44 which suggests that it could grow by 16.85%. Given that Thermo Fisher Scientific, Inc. has higher upside potential than Sotera Health Co., analysts believe Thermo Fisher Scientific, Inc. is more attractive than Sotera Health Co..

Thermo Fisher Scientific, Inc. has a beta of 0.928, which suggesting that the stock is 7.166% less volatile than S&P 500. In comparison Sotera Health Co. has a beta of 1.819, suggesting its more volatile than the S&P 500 by 81.894%.

Thermo Fisher Scientific, Inc. has a quarterly dividend of $0.43 per share corresponding to a yield of 0.34%. Sotera Health Co. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Thermo Fisher Scientific, Inc. pays 9.7% of its earnings as a dividend. Sotera Health Co. pays out -- of its earnings as a dividend. Thermo Fisher Scientific, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Thermo Fisher Scientific, Inc. quarterly revenues are $12.2B, which are larger than Sotera Health Co. quarterly revenues of $311.3M. Thermo Fisher Scientific, Inc.'s net income of $2B is higher than Sotera Health Co.'s net income of $48.4M. Notably, Thermo Fisher Scientific, Inc.'s price-to-earnings ratio is 28.80x while Sotera Health Co.'s PE ratio is 90.62x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Thermo Fisher Scientific, Inc. is 4.33x versus 4.34x for Sotera Health Co.. Usually stocks with elevated PS ratios are considered overvalued.

Veracyte, Inc. has a net margin of 16.21% compared to Thermo Fisher Scientific, Inc.'s net margin of 14.51%. Thermo Fisher Scientific, Inc.'s return on equity of 13.23% beat Veracyte, Inc.'s return on equity of 2.52%.

Thermo Fisher Scientific, Inc. has a consensus price target of $666.46, signalling upside risk potential of 30.44%. On the other hand Veracyte, Inc. has an analysts' consensus of $47.67 which suggests that it could grow by 33.78%. Given that Veracyte, Inc. has higher upside potential than Thermo Fisher Scientific, Inc., analysts believe Veracyte, Inc. is more attractive than Thermo Fisher Scientific, Inc..

Thermo Fisher Scientific, Inc. has a beta of 0.928, which suggesting that the stock is 7.166% less volatile than S&P 500. In comparison Veracyte, Inc. has a beta of 1.913, suggesting its more volatile than the S&P 500 by 91.288%.

Thermo Fisher Scientific, Inc. has a quarterly dividend of $0.43 per share corresponding to a yield of 0.34%. Veracyte, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Thermo Fisher Scientific, Inc. pays 9.7% of its earnings as a dividend. Veracyte, Inc. pays out -- of its earnings as a dividend. Thermo Fisher Scientific, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Thermo Fisher Scientific, Inc. quarterly revenues are $12.2B, which are larger than Veracyte, Inc. quarterly revenues of $131.9M. Thermo Fisher Scientific, Inc.'s net income of $2B is higher than Veracyte, Inc.'s net income of $19.1M. Notably, Thermo Fisher Scientific, Inc.'s price-to-earnings ratio is 28.80x while Veracyte, Inc.'s PE ratio is 93.86x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Thermo Fisher Scientific, Inc. is 4.33x versus 5.72x for Veracyte, Inc.. Usually stocks with elevated PS ratios are considered overvalued.